von Redaktion LCGC | Mai 15, 2011
Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, Papachristou I,...
von Redaktion LCGC | März 15, 2011
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial (ZEAL) De Boer RH, Arrieta O, Yang C-H, Gottfried M, Chan V, Raats J, De Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P,...
von Redaktion LCGC | Feb. 15, 2011
Molecular diagnostics of lung cancer for treatment stratification Heukamp LC, Wolf J, Buettner R Journal: Der Internist Vol 52, No 2, February 2012, doi: 10.1007/s00108-010-2698-yVeröffentlichung: Februar...
von Redaktion LCGC | Dez. 15, 2010
Focal amplification of FGFR1 associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer Weiss J, Sos ML, Seidel D, Peifer M, Heuckmann JM, Ulrich RK, Menon R, Maier S, Leenders F, Zander T, Gabler F, Fischer F, Heynck S, Koker M, Schöttle...
von Redaktion LCGC | Nov. 15, 2010
Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer Chmielecki J, Peifer M, Jia P, Socci ND, Hutchinson K, Viale A, Zhao Z, Thomas RK, Pao W Journal:...
